Skip to main content
CMPS
NASDAQ Life Sciences

FDA Accelerates COMP360 Review; Company Reports $466M Cash, Runway into 2028

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare Facility Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$9.9
Mkt Cap
$900.324M
52W Low
$2.25
52W High
$10.21
52W Position info
340% above low
Off High info
3.0% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

CMPS has more than doubled off its 52-week low of $2.25.

Summary

COMPASS Pathways announced accelerated regulatory progress for its lead drug COMP360, including a rolling FDA submission and a priority review voucher, alongside a significantly strengthened cash position of $466 million, extending its financial runway into 2028.


Key Events · Product Development and Regulatory · CMPS

  • FDA Grants Rolling NDA Submission

    The FDA granted a rolling New Drug Application (NDA) submission and review request for COMP360 in treatment-resistant depression, based on the strength of positive Phase 3 data. This accelerates the regulatory pathway, with sections of the NDA already submitted and the final submission on track for Q4 2026.

  • Awarded National Priority Review Voucher (CNPV)

    COMPASS Pathways was awarded a Commissioner's National Priority Review Voucher (CNPV) for COMP360, which has the potential to accelerate the FDA's review time to be completed within 1-2 months.

  • Strong Cash Position and Extended Runway

    The company reported a robust cash and cash equivalents balance of $466.0 million as of March 31, 2026. This cash position is expected to fund operating expenses and capital expenditure requirements into 2028, well beyond the anticipated commercial launch.

  • Q1 2026 Financial Results

    COMPASS Pathways reported a net income of $91.2 million for the three months ended March 31, 2026, primarily driven by a $130.9 million non-cash gain on fair value adjustment related to warrants.


Analysis · CMPS · Life Sciences

This 8-K, accompanying the Q1 2026 earnings release, delivers multiple highly positive updates. The FDA's grant of a rolling NDA submission and the award of a National Priority Review Voucher significantly accelerate the regulatory pathway for COMP360, the company's lead psychedelic treatment for treatment-resistant depression. This de-risks the approval timeline and signals strong regulatory confidence. Concurrently, the company reported a robust cash position of $466 million, extending its financial runway into 2028. This addresses previous liquidity concerns and provides ample capital through the anticipated commercial launch, strengthening the company's long-term viability. The stock is currently trading near its 52-week high, reflecting the market's positive reaction to these developments.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 49.5% of the 210 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CMPS was trading at $9.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $900.3M. The 52-week trading range was $2.25 to $10.21. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CMPS - Latest Insights

CMPS
Nov 09, 2026, 6:30 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $8.90
Real-time Price: $8.80 info
Change: -$0.100 (-1%) info
Market Cap: $1.292B info
CMPS
Nov 03, 2026, 8:07 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $9.21
Real-time Price: $8.80 info
Change: -$0.410 (-4%) info
Market Cap: $1.292B info
CMPS
Nov 03, 2026, 6:30 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $9.50
Real-time Price: $8.80 info
Change: -$0.700 (-7%) info
Market Cap: $1.292B info
CMPS
Sep 23, 2026, 3:15 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $14.75
Real-time Price: $8.80 info
Change: -$5.95 (-40%) info
Market Cap: $1.292B info
CMPS
Sep 09, 2026, 1:18 PM EDT
Source: Benzinga
Importance Score:
8
Price at Filing: $15.30
Real-time Price: $8.80 info
Change: -$6.49 (-42%) info
Market Cap: $1.292B info